You are here
PAI LIFE SCIENCES INC
http://www.pailifesciences.com
UEI: MSMLUCM9DRT6
# of Employees: 6
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Evaluation of a Next Generation SchistoShield Vaccine
Amount: $300,000.00ABSTRACT Schistosomiasis is a major parasitic disease which could impact one billion people with 252 million currently infected and 779 million at risk to acquire the infection in 74 countries. Curren ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
LATE STAGE ADJUVANT MIMICS BASED ON TLR4 AGONISTS
Amount: $597,953.00The proprietary combination adjuvants AS01 and AS04 are used in approved vaccines (Shingrix and Cervarix, respectively). Another successful adjuvant, GLA-SE, is currently in late-stage clinical trials ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines
Amount: $243,000.00ABSTRACT: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in late 2019 causing Coronavirus Disease 2019 (COVID-19) and within months became a worldwide pandemic - as of the writin ...
SBIRPhase I2021Department of Health and Human Services Centers for Disease Control and Prevention -
A Vaccine for Schistosomiasis, "SchistoShield"
Amount: $1,719,617.00PROJECT SUMMARY Schistosomiasis is a major parasitic disease which could impact up to a billion people in 74 countries. Current control strategies rely primarily on anti-parasitic drugs alone (praziqu ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
A Vaccine for Lymphatic Filariasis, LFGuard™
Amount: $3,000,000.00PROJECT SUMMARY Lymphatic filariasis (LF) is a mosquito-transmitted, neglected tropical disease (NTD) affecting over 120 million people living in 72 countries. Current control strategies for LF infect ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
A Self-Replicating RNA Vaccine Against HIV-1 Delivered Using A Nanoparticle Adjuvant
Amount: $299,184.00An effective vaccine against HIV offers the best chance to stop the global epidemic but remains elusive to dateResearch has primarily focused on subunit monomerice ggpor gpor trimeric antigensthe form ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Development of a Prophylactic Onchocerciasis Vaccine
Amount: $2,961,685.00Humanriver blindnessis caused by a filarial parasite and is a serious neglected tropical disease contributing to blindnessskin diseaseand chronic disability in the developing worldEstimates from the G ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
Production and Validation of Sj-p80 as a Veterinary Schistosomiasis Vaccine
Amount: $224,999.00Project Summary More thanbillion people are at risk worldwide for developing schistosomiasis caused by one of five species of SchistosomaTwo species that cause the most human diseaseSchistosoma japoni ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer
Amount: $1,277,560.00PROJECT SUMMARY A central mechanism of tumor drug resistance is the maintenance of tight junctions between malignant cells preventing penetration of molecules into the tumor microenvironment. We have ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
Process Development for a Lymphatic Filariasis Vaccine, (LFGuard)
Amount: $224,988.00PROJECT SUMMARYLymphatic filariasisLFis one of only a small number of diseases classified as potentially eradicableInthe World Health Assembly passed a resolution to eliminate LF as a public health pr ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health